UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000011294 |
|---|---|
| Receipt number | R000013232 |
| Scientific Title | Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE) |
| Date of disclosure of the study information | 2013/09/30 |
| Last modified on | 2017/09/19 14:14:56 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2013/07/26 20:52:34 | ||
| 2 | Update | 2013/07/28 07:57:48 | UMIN ID1 |
|
| 3 | Update | 2013/11/07 21:30:12 | Recruitment status Anticipated trial start date |
|
| 4 | Update | 2013/11/07 21:50:46 | Recruitment status Anticipated trial start date |
|
| 5 | Update | 2013/11/15 17:16:18 | Recruitment status |
|
| 6 | Update | 2014/01/27 22:57:02 | Email |
|
| 7 | Update | 2014/01/31 21:09:46 | Institutions |
|
| 8 | Update | 2014/02/26 21:19:45 | Email1 |
|
| 9 | Update | 2017/09/19 10:04:48 | Recruitment status |
|
| 10 | Update | 2017/09/19 14:14:56 | Last follow-up date Date of closure to data entry Date trial data considered complete |
